Sutro Biopharma Inc (FRA:S090)

Q4 2024 Sutro Biopharma Inc Earnings Call Transcript

Mar 13, 2025 / 09:00 PM GMT

Release Date Price: €11.7 (+0.86%)

Transcript 10-K8-K

Key Points

Positve

Sutro Biopharma Inc (STRO) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction.
The company's cash runway has been extended into at least Q4 of 2026, providing financial stability for the near future.
Sutro Biopharma Inc (STRO) has established external manufacturing partnerships, allowing for scalable production capabilities.
The company's proprietary technology enables precise design of ADCs, offering unique advantages over conventional methods.
Sutro Biopharma Inc (STRO) has attracted world-class partners such as Astellas and Ipsen, highlighting the potential and credibility of its platform.

Negative

Sutro Biopharma Inc (STRO) is reducing its workforce by nearly 50%, which may impact employee morale and operational capacity.
The company has deprioritized the development of Levelta due to limited resources, potentially missing out on its full potential.
There is a challenging macro environment affecting Sutro Biopharma Inc (STRO)'s ability to advance certain programs independently.
The decision to externalize manufacturing capabilities may lead to dependency on external partners for production.
The company faces competition from other firms, such as Pfizer, in the ADC space, which could impact its market position.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

STRO.OQ - Sutro Biopharma Inc
Q4 2024 Sutro Biopharma Inc Earnings Call
Mar 13, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Sutro BioPharma 2025 Business Update webcast. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Jane Chung, Chief Executive Officer of Sutro. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon and thank you all for joining us on the call today.

Here with me are Doctor Hans Peter Gerber, our Chief Scientific Officer, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.